Bridgette L Kram1, Shawn J Kram2, Kelli R Brooks3. 1. Duke University Hospital, DUMC Box 3089, Durham, NC, United States 27710. Electronic address: Bridgette.Kram@duke.edu. 2. Duke University Hospital, DUMC Box 3089, Durham, NC, United States 27710. Electronic address: Shawn.Kram@duke.edu. 3. Duke University Hospital, DUMC Box 3089, Durham, NC, United States 27710. Electronic address: Kelli.Brooks@dm.duke.edu.
Abstract
PURPOSE: The purpose of the study was to determine the downstream implications of atypical antipsychotic (AAP) prescribing in the intensive care unit (ICU), including discharge prescribing practices, monitoring, and attributable adverse drug events. MATERIALS AND METHODS: This retrospective cohort study included patients at least 18 years of age admitted to an ICU that received at least 2 doses of an AAP for documented delirium or avoidance of a deliriogenic medication. Exclusion criteria were documentation of an AAP as a home medication or initiation for a psychiatric indication unrelated to delirium (eg, schizophrenia). RESULTS: During the 8-month study period, 156 patients were included and 133 (85.2%) patients survived to hospital discharge. Of the survivors, AAP therapy was continued for 112 (84.2%) patients upon ICU transfer and for 38 (28.6%) patients upon hospital discharge. A majority of these patients had evidence of delirium resolution or no indication for continuation documented at discharge. Of the 127 patients with an electrocardiogram ordered during AAP therapy, QTc prolongation occurred in 49 (31.4%) patients. An adverse drug event leading to drug discontinuation was documented in 16 (10.2%) patients. CONCLUSIONS: Because of significant patient-centered implications, AAPs initiated in the ICU require continued evaluation for indication to avoid prolonged and possibly unnecessary use.
PURPOSE: The purpose of the study was to determine the downstream implications of atypical antipsychotic (AAP) prescribing in the intensive care unit (ICU), including discharge prescribing practices, monitoring, and attributable adverse drug events. MATERIALS AND METHODS: This retrospective cohort study included patients at least 18 years of age admitted to an ICU that received at least 2 doses of an AAP for documented delirium or avoidance of a deliriogenic medication. Exclusion criteria were documentation of an AAP as a home medication or initiation for a psychiatric indication unrelated to delirium (eg, schizophrenia). RESULTS: During the 8-month study period, 156 patients were included and 133 (85.2%) patients survived to hospital discharge. Of the survivors, AAP therapy was continued for 112 (84.2%) patients upon ICU transfer and for 38 (28.6%) patients upon hospital discharge. A majority of these patients had evidence of delirium resolution or no indication for continuation documented at discharge. Of the 127 patients with an electrocardiogram ordered during AAP therapy, QTc prolongation occurred in 49 (31.4%) patients. An adverse drug event leading to drug discontinuation was documented in 16 (10.2%) patients. CONCLUSIONS: Because of significant patient-centered implications, AAPs initiated in the ICU require continued evaluation for indication to avoid prolonged and possibly unnecessary use.
Authors: Natalia Jaworska; Stephana Julia Moss; Karla D Krewulak; Zara Stelfox; Daniel Niven; Zahinoor Ismail; Lisa Burry; Kirsten Fiest Journal: BMJ Open Date: 2022-06-29 Impact factor: 3.006
Authors: Joanna L Stollings; Sarah L Bloom; Li Wang; E Wesley Ely; James C Jackson; Carla M Sevin Journal: Ann Pharmacother Date: 2018-02-18 Impact factor: 3.154
Authors: Antoinette B Coe; Rebecca E Bookstaver; Andrew C Fritschle; Michael T Kenes; Pamela MacTavish; Rima A Mohammad; Robert J Simonelli; Jessica A Whitten; Joanna L Stollings Journal: Hosp Pharm Date: 2019-01-28
Authors: Christina S Boncyk; Emily Farrin; Joanna L Stollings; Kelli Rumbaugh; Jo Ellen Wilson; Matt Marshall; Xiaoke Feng; Matthew S Shotwell; Pratik P Pandharipande; Christopher G Hughes Journal: Anesth Analg Date: 2021-09-01 Impact factor: 6.627
Authors: Jason E Tomichek; Joanna L Stollings; Pratik P Pandharipande; Rameela Chandrasekhar; E Wesley Ely; Timothy D Girard Journal: Crit Care Date: 2016-11-24 Impact factor: 9.097
Authors: Bertrand Guidet; Helene Vallet; Jacques Boddaert; Dylan W de Lange; Alessandro Morandi; Guillaume Leblanc; Antonio Artigas; Hans Flaatten Journal: Ann Intensive Care Date: 2018-11-26 Impact factor: 6.925
Authors: Kunal Karamchandani; Robert S Schoaps; Anthony Bonavia; Amit Prasad; Ashley Quintili; Erik B Lehman; Zyad J Carr Journal: Ther Adv Drug Saf Date: 2018-11-02
Authors: Liesbeth B E Bosma; Nicole G M Hunfeld; Rogier A M Quax; Edmé Meuwese; Piet H G J Melief; Jasper van Bommel; SiokSwan Tan; Maaike J van Kranenburg; Patricia M L A van den Bemt Journal: Ann Intensive Care Date: 2018-02-07 Impact factor: 6.925